For example, in patients at high risk, prophylactic medication of recombinant human thrombopoietin (rh-TPO) or thrombopoietin receptor agonists (TPO-RA) might be administered to prevent severe thrombocytopenia and to maintain chemotherapy dose intensity (Kuter, 2022; Jin et al., 2021; Wang et al., 2018). This evidence concerns the gene MPL and Thrombocytopenia.